Non-Alcoholic Steatohepatitis (NASH)
Conditions
Keywords
PPARs, NASH, Non-Alcoholic Steatohepatitis, Liver Diseases, Fibrosis
Brief summary
Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver cancer. NAFLD (Non Alcoholic Fatty Liver Disease) is considered as the most common form of chronic liver disease in adults in the United States, Australia, Asia and Europe. In the USA, the estimated prevalence of NAFLD is 20-30% of the adult population. Non-alcoholic Steatohepatitis (NASH) is a progressing form of NAFLD, which corresponds to hepatic steatosis associated with inflammation and liver cell injury upon microscopic examination of a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and deserves serious medical management. Up to now, there is no effective drug which has clearly demonstrated therapeutic efficacy which may help lifestyle and dietary recommendations in the resolution of NASH. In this context, GENFIT is developing a new liver targeted drug candidate, GFT505, for the treatment of NASH and the reduction of multiple cardiometabolic risk factors associated with the metabolic syndrome and type 2 Diabetes. This phase IIb study will evaluate the efficacy and safety of GFT505 80mg and 120mg once daily for 52 weeks on the reversal of NASH without worsening of fibrosis, based on liver biopsy assessments.
Detailed description
The study duration per patient will be 80 weeks. A screening period (from 4 to 16 weeks) will precede a 52-week double-blind treatment period and a 3 months follow-up period. The study will be conducted in 270 patients (90 patients in the placebo arm, 90 patients in the GFT505 80mg arm, and 90 patients in the GFT505 120mg arm). Enrollment will be performed in two phases: during the first phase, the patients will receive either GFT505 at a dose of 80 mg either the placebo. An independent expert committee will review the safety data when 45 patients receiving the dose at 80 mg will have been treated for 6 months. The committee approval will be necessary to start the second phase, while the patients will receive either GFT505 at a dose of 80 mg, or GFT505 at a dose of 120 mg or the placebo.
Interventions
Sponsors
Naturalpha
Premier Research
Genfit
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Males or females (females must be either of non-child bearing potential or using an efficient double contraception). For male participants, contraceptive measures must be taken during the study, either by the male participant or his female partner. * Body Mass Index ≤ 45 kg/m². * Patients agree to have one liver biopsy during the screening period for diagnostic purpose (if no historical biopsy within 6 months before randomization is available) and one at the end of the treatment period for assessment of the treatment effects. * For hypertensive patients, hypertension must be controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study). * Patients treated with vitamin E (\>400IU/d), or Polyunsaturated fatty acids (\>2g/day)or Ursodeoxycholic acid can be included if drugs are stopped at least 3 months prior to diagnostic liver biopsy and up to the end of the study. * Histological confirmation of steatohepatitis on a diagnostic liver biopsy. Histological diagnostic is confirmed by central reading of the slides (steatosis \> 5% + lobular inflammation, any grade + ballooning, any amount). * For patients with Type 2 Diabetes, glycemia must be controlled (Glycosylated Haemoglobin A1c ≤8.5%). If glycemia is controlled by anti-diabetic drugs, qualitative change is not permitted within 6 months prior to randomization and should be avoided during the study. Treatments with metformin, Dipeptidyl Peptidase 4 inhibitors, Glucagon-like peptide-1 agonists, sulfamides, insulin are authorized. Sulfamides and insulin are permitted if glycemia is self-monitored by the patient.
Exclusion criteria
* Known heart failure (Grade I to IV of New York Heart Association classification). * Weight loss of more than 5% within 6 months prior to randomization. * History of bariatric surgery. * Uncontrolled Blood Pressure. * Type 1 diabetes patients. * Patients who had an acute cardiovascular episode within the 6 months prior to screening, or with a history of coronary angioplasty, history of stroke, Transient Ischemic Attack, Coronary Heart Disease. * Compensated and uncompensated cirrhosis. Notably, NASH patients with fibrosis stage = 4 according to the NASH CRN fibrosis staging system are excluded. * Known alcohol and/or any other drug abuse or dependence in the last five years. * Pregnant or lactating females. * Other well documented causes of chronic liver disease * Known intolerance or contra-indication to the list of excipients of GFT505. * Evidence of any other unstable or, untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric disorder. * Positive HBsAg (Hepatitis B Surface Antigen), Positive anti-HIV, positive HCV-RNA (Hepatitis C Virus). * Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone \> 2X the upper limit of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to screening is permitted. * Significant renal disease, including nephritic syndrome, chronic renal failure (defined as creatinine clearance \< 60 mL/mn and serum creatinine \>180 μmol/L). * Unexplained serum creatine phosphokinase (CPK) \> 3X the upper limit of normal (ULN). Patients with a reason for CPK elevation may have the measurement repeated prior to randomization; a CPK retest \> 3X ULN leads to exclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | Percentage of responders from baseline to Week 52 defined by the disappearance of steatohepatitis (ie, participants no longer meeting the criteria for steatohepatitis) without worsening of fibrosis. Worsening of fibrosis was evaluated using Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis staging system and defined as: * Progression to stage 3 or 4 for participants at stage 0, 1 or 2 on diagnostic liver biopsy * Progression to stage 4 for participants at stage 3 on diagnostic liver biopsy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate the number of participants with at least a 2 point decrease from baseline in Non-alcoholic Fatty Liver Disease Activity Score (NAS) after 52 weeks of daily administration of GFT505 80mg or 120mg. The NAS refers to the severity of ongoing liver injury as assessed by a liver biopsy and is used to assess the activity of the disease. It is based on the NASH CRN methodology for scoring the severity of steatosis (score of 0 to 3), inflammation (score of 0 to 3), and hepatocellular ballooning (score of 0 to 2), with a maximum score of 8. A total NAS score of five or greater correlates with the diagnosis of steatohepatitis. In table below for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 2 participants (out of 10 participants analysed with a baseline NAS at 3) had at Least 2 points decrease on their NAS after 52 weeks of daily administration of GFT505 80mg. It corresponds to 20% (2 out of 10). |
| Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in steatosis score of at least 1 point between baseline and Week 52. Steatosis is assessed by a liver biopsy and evaluated on a scale of 0 to 3 with higher scores indicating more severe steatosis. A score of 0 indicating a lower severity with low parenchymal involvement (\<5%), while a score of 3 is indicative of higher involvment/severity (\> 66%). In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease Steatosis Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10). |
| Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in lobular inflammation score of at least 1 point between baseline and Week 52. Lobular inflammation is assessed by a liver biopsy and evaluated on a scale of 0 to 3. A score of 0 indicating the absence of inflammation loci, while a score of 3 is indicative of a higher degree of inflammation with more than 4 inflammation loci 200 x field. In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Lobular Inflammation Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10). |
| Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in aspartate transaminase/alanine aminotransferase ratio |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK 18-M65 (non-invasive markers of fibrosis and steatosis). |
| Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in ballooning score of at least 1 point between baseline and Week 52. Ballooning is assessed by a liver biopsy and evaluated on a scale of 0 to 2 with higher scores indicating more severe ballooning (0: No ballooned cells, 1: Few \[rare but definite\] ballooned hepatocytes; 2: Many ballooned cells/prominent ballooning). In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 4 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Ballooning Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10). |
| Changes From Baseline to Week 52 in the Stages of Fibrosis | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in stages of fibrosis (based on Non-Alcoholic Steatohepatitis Clinical Research Network \[NASH CRN\] scoring). Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. |
| Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in liver enzymes. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK18 M30 (non-invasive markers of fibrosis and steatosis). Participants with missing data for CK18 M30 at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in adiponectin (non-invasive markers of fibrosis and steatosis). |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in ferritin (non-invasive markers of fibrosis and steatosis). Participants with missing data for Ferritin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in FG19 and FG21 (non-invasive markers of fibrosis and steatosis). |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in alpha2 macroglobulin (a non-invasive marker of fibrosis and steatosis). Participants with missing data for Alpha2 Macroglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in hyaluronic acid, N-terminal pro-peptide of collagen type III (PIIINP), and tissue inhibitor of matrix metalloprotease-1 (TIMP-1) (non-invasive markers of fibrosis and steatosis). |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | Fibrotest combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT with adjustment for age and gender. Fibrotest is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e\^-z). Calculated score range from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for Fibrotest and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Fibrotest calculated in 81 participants is -0.06 with a standard deviation of 0.08. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | SteatoTest combines α2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, and ALT, adjusted for patient's age, sex, weight, and height. Patented formula. Calculated score range from 0 (no steatosis) to 1 (severe steatosis) In below table for Steatotest and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Steatotest calculated in 81 participants is -0.09 with a standard deviation of 0.11. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. Score is calculated using the following formula: -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis. In below table for Angulo index and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Angulo index calculated in 82 participants is 0.06 with a standard deviation of 0.53. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | Enhanced Liver Fibrosis (ELF) combines measurements of tissue inhibitor of metalloprotein-ases-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) . The ELF score is calculated as : 2.278 + 0.851 ln (HA) + 0.751 ln (PIIINP) + 0.394 ln (TIMP-1). ELF score range from An ELF score of less than 7.7 indicates no fibrosis. An ELF score greater than or equal to 9.8 indicates severe fibrosis. An ELF score of 11.3 or greater indicates cirrhosis. A decrease in ELF score represents a positive outcome In below table for Enhanced Liver Fibrosis and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Enhanced Liver Fibrosis calculated in 81 analysed participants is -0.01 with a standard deviation of 0.54. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | The Fatty Liver Index (FLI) combines triglycerides, BMI, GGT and Waist circumference. FLI is calculated as : (e0.953×loge\[triglycerides\]+0.139× Body Mass Index\[BMI\]+0.718×loge Gamma- Glutamyl Transferase \[GGT\]+0.053×waistcircumference-15.745)/ (1 +e0.953×loge\[triglycerides\]+0.139×BMI+0.718×loge \[GGT\]+0.053×waistcircumference-15.745) × 100. Calculated index range from 0 to 100. FLI score below 30 indicate absence of Fatty Liver and FLI Score of 60 and above indicates presence of Fatty Liver. In below table for Fatty Liver Index and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Fatty Liver Index calculated in 82 analysed participants is -7.94 with a standard deviation of 11.74. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | Fibrometer combines Platelets, AST, ALT, ferritin, glucose (fasting plasma), Weight and gender. Patented formula. Score ranges from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for Fibrometer and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Fibrometer calculated in 81 analysed participants is 0.04 with a standard deviation of 0.23. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in total bilirubin and conjugated bilirubin (non-invasive markers of fibrosis and steatosis). |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in prothrombin ratio (non-invasive marker of fibrosis and steatosis). The Prothrombin ratio is the ratio of a participants measured prothrombin time (in seconds) to the normal laboratory reference prothrombin time. Participants with missing data for Prothrombin ratio at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in international normalized ratio (INR; non-invasive marker of fibrosis and steatosis). Participants with missing data for International Normalized Ratio (INR) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in lipid parameters (used to assess cardiovascular risk) |
| Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in secondary outcomes related to biochemistry |
| Changes From Baseline to Week 52 in Insulin Resistance: Leptin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in leptin (to assess insulin resistance). |
| Changes From Baseline to Week 52 in Insulin Resistance: Insulin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in insulin (to assess insulin resistance). Participants with missing data for Insulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: C Peptide | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in C peptide (to assess insulin resistance). Participants with missing data for C Peptide at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in homeostatic model assessment-insulin resistance (HOMA-IR; to assess insulin resistance). The HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/l) / 22.5 A decrease in HOMA-IR indicates a positive outcome. HOMA-IR values of greater than 1.9 indicates early insulin resistance and levels above 2.9 indicate significant insulin resistance. Participants with missing data for HOMA-IR at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in free fatty acids (FFA; to assess insulin resistance). Participants with missing data for Free Fatty Acids (FFA) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in plasma glucose (to assess insulin resistance). Participants with missing data for Plasma Glucose at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in glycosylated haemoglobin A1c (HbA1c; to assess insulin resistance). Participants with missing data for Haemoglobin A1c (HbA1c) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in Fructosamine (to assess insulin resistance). |
| Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in fibrinogen and haptoglobin (inflammatory markers). |
| Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in tumour necrosis factor alpha and interleukine 6 (inflammatory markers). |
| Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in plasminogen activator inhibitor 1 (PAI-1; inflammatory marker). Participants with missing data for Plasminogen Activator Inhibitor 1 (PAI-1) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow |
| Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in C-Reactive Protein (CRP; inflammatory marker). |
| Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine (safety markers; renal function parameter). |
| Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine clearance (safety marker; renal function parameter). |
| Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in uric acid (safety marker; renal function parameter). |
| Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg the change from baseline to Week 52, in Non-alcoholic Fatty Liver Disease Activity Score (NAS score). NAS score is a composite score equal to the sum of the steatosis grade (0 to 3), lobular inflammation grade (0 to 3) and hepatocellular ballooning grade (0 to 2). The overall scale of the NAS is 0 to 8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome. |
| Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in cystatin C (safety marker; renal function parameter). Participants with missing data for Cystatin C at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in beta2-microglobulin (safety marker; renal function parameter). Participants with missing data for Beta2-microglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in N-terminal prohormone of brain natriuretic peptide (NT-proBNP; safety marker; cardiac function parameter). Participants with missing data for NT-proBNP at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in troponin T (safety marker; cardiac function parameter). Participants with missing data for Troponin T at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow. |
| Changes From Baseline to Week 52 in Body Weight | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in body weight. |
| Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter) | Baseline (Visit 2; Week 0) to Visit 8 (Week 52) | To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in blood urea nitrogen (BUN; safety marker; renal function parameter). |
Countries
Belgium, France, Germany, Italy, Netherlands, Romania, Spain, United Kingdom, United States
Participant flow
Recruitment details
Recruitment for the GFT505-212-7 study began in September 2012. This was a phase IIb, double-blind, randomized, placebo-controlled study conducted in three parallel groups: placebo, GFT505 80mg and GFT505 120mg (after DSMB review of 6 month safety data of the 80mg dose on at least 50% of participants) once daily for 52 weeks.
Pre-assignment details
Random allocation was done in two phases. In the first study phase, participants were randomly allocated to GFT505 80 mg or placebo (ratio 2:1). In the second study phase (after Data and Safety Monitoring Board review of 6-month safety data of the 80-mg dose on at least 50% of participants), participants were assigned to GFT505 120 mg or placebo (ratio 2:1) in order to balance the 3 treatments in a 1:1:1 ratio basis.
Participants by arm
| Arm | Count |
|---|---|
| GFT505 80mg Hard gelatin capsules dosed at 40mg, oral administration. 3 capsules per day (2 capsules of GFT505 40 mg and 1 capsule of placebo), before breakfast with a glass of water. | 93 |
| GFT505 120mg Hard gelatin capsules dosed at 40mg, oral administration. 3 capsules of GFT505 40 mg per day, before breakfast with a glass of water. | 89 |
| Placebo Hard gelatin capsules, oral administration. Capsules of placebo were identical to capsules of investigational product to ensure double-blind conditions.
3 placebo capsules per day, before breakfast with a glass of water. | 92 |
| Total | 274 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Follow-up Period (to Visit 9) | Lost to Follow-up | 1 | 2 | 1 |
| Follow-up Period (to Visit 9) | Withdrawal by Subject | 0 | 1 | 0 |
| Treatment Period (Visit 2 to Visit 8) | Adverse Event | 6 | 7 | 4 |
| Treatment Period (Visit 2 to Visit 8) | Lost to Follow-up | 0 | 0 | 1 |
| Treatment Period (Visit 2 to Visit 8) | Non-compliance | 1 | 0 | 1 |
| Treatment Period (Visit 2 to Visit 8) | Protocol Violation | 1 | 0 | 1 |
| Treatment Period (Visit 2 to Visit 8) | Randomized and not treated | 0 | 1 | 0 |
| Treatment Period (Visit 2 to Visit 8) | Withdrawal by Subject | 1 | 3 | 7 |
Baseline characteristics
| Characteristic | GFT505 120mg | Placebo | GFT505 80mg | Total |
|---|---|---|---|---|
| Age, Continuous | 52.88 years STANDARD_DEVIATION 11.63 | 52.88 years STANDARD_DEVIATION 11.99 | 53.26 years STANDARD_DEVIATION 11.02 | 53.01 years STANDARD_DEVIATION 11.51 |
| Body Mass Index (BMI) | 31.04 kg/m^2 STANDARD_DEVIATION 4.39 | 30.91 kg/m^2 STANDARD_DEVIATION 4.15 | 31.80 kg/m^2 STANDARD_DEVIATION 5.2 | 31.25 kg/m^2 STANDARD_DEVIATION 4.61 |
| Height | 170.21 cm STANDARD_DEVIATION 10.69 | 169.21 cm STANDARD_DEVIATION 10.23 | 167.77 cm STANDARD_DEVIATION 9.3 | 169.05 cm STANDARD_DEVIATION 10.09 |
| Race/Ethnicity, Customized Race Asian | 6 Participants | 1 Participants | 0 Participants | 7 Participants |
| Race/Ethnicity, Customized Race Black | 5 Participants | 3 Participants | 2 Participants | 10 Participants |
| Race/Ethnicity, Customized Race Caucasian | 71 Participants | 85 Participants | 88 Participants | 244 Participants |
| Race/Ethnicity, Customized Race Other | 7 Participants | 3 Participants | 3 Participants | 13 Participants |
| Sex: Female, Male Female | 42 Participants | 37 Participants | 44 Participants | 123 Participants |
| Sex: Female, Male Male | 47 Participants | 55 Participants | 49 Participants | 151 Participants |
| Type 2 diabetes Type 2 diabetes (No) | 52 participants | 59 participants | 56 participants | 167 participants |
| Type 2 diabetes Type 2 diabetes (Yes) | 37 participants | 33 participants | 37 participants | 107 participants |
| Waist Circumference | 106.26 cm STANDARD_DEVIATION 10.28 | 104.68 cm STANDARD_DEVIATION 10.52 | 106.41 cm STANDARD_DEVIATION 13.09 | 105.78 cm STANDARD_DEVIATION 11.37 |
| Weight | 90.15 kg STANDARD_DEVIATION 15.57 | 88.72 kg STANDARD_DEVIATION 15.79 | 89.62 kg STANDARD_DEVIATION 17.76 | 89.49 kg STANDARD_DEVIATION 16.36 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 93 | 0 / 89 | 0 / 92 |
| other Total, other adverse events | 85 / 93 | 86 / 89 | 85 / 92 |
| serious Total, serious adverse events | 12 / 93 | 14 / 89 | 9 / 92 |
Outcome results
Primary
Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)
Percentage of responders from baseline to Week 52 defined by the disappearance of steatohepatitis (ie, participants no longer meeting the criteria for steatohepatitis) without worsening of fibrosis. Worsening of fibrosis was evaluated using Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis staging system and defined as: * Progression to stage 3 or 4 for participants at stage 0, 1 or 2 on diagnostic liver biopsy * Progression to stage 4 for participants at stage 3 on diagnostic liver biopsy
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Analysis was done of the efficacy evaluable sample, (Efficacy Evaluable Set) formed by participants with liver biopsy available at end-of-treatment and considered as the Intent to Treat population in the protocol. Robustness analysis was also performed in the Full Analysis Set, formed by all randomized participants that received at least one dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GFT505 80mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Responders | 21 Participants |
| GFT505 80mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Non-responders | 61 Participants |
| GFT505 80mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Responders | 21 Participants |
| GFT505 80mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Non-responders | 72 Participants |
| GFT505 120mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Non-responders | 70 Participants |
| GFT505 120mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Responders | 19 Participants |
| GFT505 120mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Responders | 19 Participants |
| GFT505 120mg | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Non-responders | 59 Participants |
| Placebo | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Non-responders | 76 Participants |
| Placebo | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Non-responders | 61 Participants |
| Placebo | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Full analysis set | Responders | 16 Participants |
| Placebo | Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Efficacy evaluable set | Responders | 16 Participants |
Comparison: H\_01: OR\_80 less than or equal to 1 versus H\_11 : OR\_80 greater than 1 H\_02: OR\_120 less than or equal to 1 versus H\_12 : OR\_120 greater than 1p-value: 0.853995% CI: [0.427, 2.795]Regression, Logistic
Comparison: H\_01: OR\_80 less than or equal to 1 versus H\_11 : OR\_80 greater than 1 H\_02: OR\_120 less than or equal to 1 versus H\_12 : OR\_120 greater than 1p-value: 0.81695% CI: [0.361, 2.232]Regression, Logistic
Secondary
Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg the change from baseline to Week 52, in Non-alcoholic Fatty Liver Disease Activity Score (NAS score). NAS score is a composite score equal to the sum of the steatosis grade (0 to 3), lobular inflammation grade (0 to 3) and hepatocellular ballooning grade (0 to 2). The overall scale of the NAS is 0 to 8, with higher scores indicating more severe disease. The outcome measure, change from baseline in NAFLD Activity Score (NAS), has a possible range from -8 to +8, with negative values indicating a better outcome (improvement) and positive values indicating a worse outcome.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | -0.65 NAS score | Standard Deviation 1.33 |
| GFT505 120mg | Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | -0.64 NAS score | Standard Deviation 1.68 |
| Placebo | Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | -0.45 NAS score | Standard Deviation 1.34 |
Comparison: H0: difference in least squares (LS) mean change from baseline equal to 0 H1: difference in LS mean change from baseline not equal to 0~Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.22595% CI: [-0.75, 0.2]Mixed Models Analysis
Comparison: H0: difference in least squares (LS) mean change from baseline equal to 0 H1: difference in LS mean change from baseline not equal to 0~Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.25495% CI: [-0.76, 0.2]Mixed Models Analysis
Secondary
Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in aspartate transaminase/alanine aminotransferase ratio
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio | 0.15 ratio | Standard Deviation 0.21 |
| GFT505 120mg | Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio | 0.20 ratio | Standard Deviation 0.25 |
| Placebo | Changes From Baseline to Visit 8 (Week 52) in Aspartate Transaminase/Alanine Aminotransferase Ratio | 0.01 ratio | Standard Deviation 0.25 |
p-value: <0.00195% CI: [0.06, 0.21]Mixed Models Analysis
p-value: <0.00195% CI: [0.11, 0.26]Mixed Models Analysis
Secondary
Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in liver enzymes.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Gamma-glutamyl transferase | -24.32 U/L | Standard Deviation 36.39 |
| GFT505 80mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Aspartate transaminase | 1.88 U/L | Standard Deviation 27.76 |
| GFT505 80mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alanine aminotransferase | -7.02 U/L | Standard Deviation 36.21 |
| GFT505 80mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alkaline phosphatases | -18.82 U/L | Standard Deviation 13.23 |
| GFT505 120mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alkaline phosphatases | -20.44 U/L | Standard Deviation 16.47 |
| GFT505 120mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Gamma-glutamyl transferase | -20.59 U/L | Standard Deviation 40.45 |
| GFT505 120mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alanine aminotransferase | -12.54 U/L | Standard Deviation 44.72 |
| GFT505 120mg | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Aspartate transaminase | -1.37 U/L | Standard Deviation 24.74 |
| Placebo | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alkaline phosphatases | 3.44 U/L | Standard Deviation 13.16 |
| Placebo | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Aspartate transaminase | -1.32 U/L | Standard Deviation 16.63 |
| Placebo | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Alanine aminotransferase | -3.26 U/L | Standard Deviation 24.67 |
| Placebo | Changes From Baseline to Visit 8 (Week 52) in Liver Enzymes | Gamma-glutamyl transferase | 6.22 U/L | Standard Deviation 50.64 |
Comparison: Change in alanine aminotransferase (U/L)p-value: 0.22195% CI: [-15.97, 3.71]Mixed Models Analysis
Comparison: Change in aspartate transaminase (U/L)p-value: 0.71195% CI: [-5.33, 7.81]Mixed Models Analysis
Comparison: Change in aspartate transaminase (U/L)p-value: 0.7895% CI: [-7.58, 5.7]Mixed Models Analysis
Comparison: Change in alanine aminotransferase (U/L)p-value: 0.06295% CI: [-19.4, 0.49]Mixed Models Analysis
Comparison: Change in Alkaline phosphatases (U/L)p-value: <0.00195% CI: [-27.16, -18.88]Mixed Models Analysis
Comparison: Change in Alkaline phosphatases (U/L)p-value: <0.00195% CI: [-28.04, 2.12]Mixed Models Analysis
Comparison: Change in Gamma-glutamyl transferase (U/L)p-value: <0.00195% CI: [-43.78, -19.05]Mixed Models Analysis
Comparison: Change in Gamma-glutamyl transferase (U/L)p-value: <0.00195% CI: [-41.84, -16.77]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Body Weight
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in body weight.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set (EES)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Body Weight | 0.11 kg | Standard Deviation 3.61 |
| GFT505 120mg | Changes From Baseline to Week 52 in Body Weight | -0.69 kg | Standard Deviation 4.09 |
| Placebo | Changes From Baseline to Week 52 in Body Weight | -0.04 kg | Standard Deviation 3.4 |
p-value: 0.94295% CI: [-1.12, 1.04]Mixed Models Analysis
p-value: 0.30495% CI: [-0.52, 1.66]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in C-Reactive Protein (CRP; inflammatory marker).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP) | -0.04 Log (mg/L) | Standard Deviation 0.72 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP) | -0.05 Log (mg/L) | Standard Deviation 0.81 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: C-Reactive Protein (CRP) | 0.20 Log (mg/L) | Standard Deviation 0.74 |
p-value: 0.06595% CI: [-0.42, 0.01]Mixed Models Analysis
p-value: 0.09895% CI: [-0.41, 0.03]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in fibrinogen and haptoglobin (inflammatory markers).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Fibrinogen | -0.37 g/L | Standard Deviation 0.7 |
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Haptoglobin | -0.19 g/L | Standard Deviation 0.32 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Fibrinogen | -0.37 g/L | Standard Deviation 0.79 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Haptoglobin | -0.20 g/L | Standard Deviation 0.4 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Fibrinogen | -0.05 g/L | Standard Deviation 0.66 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: Fibrinogen and Haptoglobin | Haptoglobin | 0.09 g/L | Standard Deviation 0.35 |
Comparison: Fibrinogenp-value: <0.00195% CI: [-0.54, -0.17]Mixed Models Analysis
Comparison: Fibrinogenp-value: 0.00595% CI: [-0.46, -0.08]Mixed Models Analysis
Comparison: Haptoglobinp-value: <0.00195% CI: [-0.35, -0.15]Mixed Models Analysis
Comparison: Haptoglobinp-value: <0.00195% CI: [-0.37, -0.17]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in plasminogen activator inhibitor 1 (PAI-1; inflammatory marker). Participants with missing data for Plasminogen Activator Inhibitor 1 (PAI-1) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1) | -0.51 ng/mL | Standard Deviation 3.51 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1) | 0.21 ng/mL | Standard Deviation 4.28 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: Plasminogen Activator Inhibitor 1 (PAI-1) | -0.14 ng/mL | Standard Deviation 4.74 |
p-value: 0.22995% CI: [-2, 0.48]Mixed Models Analysis
p-value: 0.46395% CI: [-1.67, 0.76]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to Week 52, in tumour necrosis factor alpha and interleukine 6 (inflammatory markers).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Tumour Necrosis Factor alpha | 1.37 pg/mL | Standard Deviation 6.14 |
| GFT505 80mg | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Interleukine 6 | 0.37 pg/mL | Standard Deviation 4.2 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Tumour Necrosis Factor alpha | -2.45 pg/mL | Standard Deviation 38.58 |
| GFT505 120mg | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Interleukine 6 | -1.14 pg/mL | Standard Deviation 10.33 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Tumour Necrosis Factor alpha | 0.19 pg/mL | Standard Deviation 10.46 |
| Placebo | Changes From Baseline to Week 52 in Inflammatory Markers: Tumour Necrosis Factor Alpha and Interleukine 6 | Interleukine 6 | -0.06 pg/mL | Standard Deviation 1.37 |
Comparison: Tumour Necrosis Factor alphap-value: 0.74295% CI: [-2.9, 4.06]Mixed Models Analysis
Comparison: Tumour Necrosis Factor alphap-value: 0.10795% CI: [-0.63, 6.43]Mixed Models Analysis
Comparison: Interleukine 6p-value: 0.36295% CI: [-0.58, 1.59]Mixed Models Analysis
Comparison: Interleukine 6p-value: 0.89495% CI: [-1.03, 1.18]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: C Peptide
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in C peptide (to assess insulin resistance). Participants with missing data for C Peptide at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: C Peptide | -0.17 nmol/L | Standard Deviation 0.55 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: C Peptide | -0.03 nmol/L | Standard Deviation 0.48 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: C Peptide | 0.12 nmol/L | Standard Deviation 0.58 |
p-value: 0.00395% CI: [-0.37, -0.08]Mixed Models Analysis
p-value: 0.06895% CI: [-0.29, 0.01]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in free fatty acids (FFA; to assess insulin resistance). Participants with missing data for Free Fatty Acids (FFA) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA) | -0.04 mmol/L | Standard Deviation 0.25 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA) | -0.04 mmol/L | Standard Deviation 0.24 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Free Fatty Acids (FFA) | 0.05 mmol/L | Standard Deviation 0.26 |
p-value: 0.09595% CI: [-0.11, 0.01]Mixed Models Analysis
p-value: 0.02295% CI: [-0.13, -0.01]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in Fructosamine (to assess insulin resistance).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine | 16.27 umol/L | Standard Deviation 27.53 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine | -8.24 umol/L | Standard Deviation 28.21 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Fructosamine | 11.29 umol/L | Standard Deviation 28.62 |
p-value: 0.495% CI: [-4.89, 12.2]Mixed Models Analysis
p-value: <0.00195% CI: [-24.99, -7.44]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in glycosylated haemoglobin A1c (HbA1c; to assess insulin resistance). Participants with missing data for Haemoglobin A1c (HbA1c) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c) | 0.22 percentage of HbA1c | Standard Deviation 0.56 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c) | 0.03 percentage of HbA1c | Standard Deviation 0.7 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Glycosylated Haemoglobin A1c (HbA1c) | 0.25 percentage of HbA1c | Standard Deviation 0.69 |
p-value: 0.73295% CI: [-0.24, 0.17]Mixed Models Analysis
p-value: 0.06295% CI: [-0.4, 0.01]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in homeostatic model assessment-insulin resistance (HOMA-IR; to assess insulin resistance). The HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/l) / 22.5 A decrease in HOMA-IR indicates a positive outcome. HOMA-IR values of greater than 1.9 indicates early insulin resistance and levels above 2.9 indicate significant insulin resistance. Participants with missing data for HOMA-IR at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR) | -1.10 HOMA-IR score | Standard Deviation 10.76 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR) | -1 HOMA-IR score | Standard Deviation 6.86 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Homeostatic Model Assessment-insulin Resistance (HOMA-IR) | 1.01 HOMA-IR score | Standard Deviation 4.96 |
p-value: 0.44895% CI: [-2.86, 1.27]Mixed Models Analysis
p-value: 0.26795% CI: [-3.25, 0.9]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Insulin
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in insulin (to assess insulin resistance). Participants with missing data for Insulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Insulin | -33.88 pmol/L | Standard Deviation 189.64 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Insulin | -26.12 pmol/L | Standard Deviation 111.76 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Insulin | 8.92 pmol/L | Standard Deviation 112.26 |
p-value: 0.30795% CI: [-50.88, 16.08]Mixed Models Analysis
p-value: 0.21395% CI: [-55.17, 12.34]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Leptin
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in leptin (to assess insulin resistance).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Leptin | -0.21 ng/mL | Standard Deviation 9.55 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Leptin | 3.51 ng/mL | Standard Deviation 10.67 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Leptin | 3.01 ng/mL | Standard Deviation 8.08 |
p-value: 0.06695% CI: [-5.79, 0.18]Mixed Models Analysis
p-value: 0.61595% CI: [-2.24, 3.77]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in plasma glucose (to assess insulin resistance). Participants with missing data for Plasma Glucose at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose | 0.17 mmol/L | Standard Deviation 1.23 |
| GFT505 120mg | Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose | 0.22 mmol/L | Standard Deviation 1.7 |
| Placebo | Changes From Baseline to Week 52 in Insulin Resistance: Plasma Glucose | 0.67 mmol/L | Standard Deviation 1.95 |
p-value: 0.07795% CI: [-0.96, 0.05]Mixed Models Analysis
p-value: 0.17295% CI: [-0.87, 0.16]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in lipid parameters (used to assess cardiovascular risk)
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Non-high Density Lipoproteins Cholesterol | -0.45 mmol/L | Standard Deviation 0.79 |
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Triglycerides | -0.33 mmol/L | Standard Deviation 0.76 |
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Cholesterol | -0.42 mmol/L | Standard Deviation 0.78 |
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | High Density Lipoproteins Cholesterol | 0.02 mmol/L | Standard Deviation 0.17 |
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Very Low Density Lipoproteins Cholesterol | -0.17 mmol/L | Standard Deviation 0.28 |
| GFT505 80mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Low Density Lipoproteins Cholesterol | -0.27 mmol/L | Standard Deviation 0.7 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Cholesterol | -0.42 mmol/L | Standard Deviation 0.72 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Non-high Density Lipoproteins Cholesterol | -0.47 mmol/L | Standard Deviation 0.71 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | High Density Lipoproteins Cholesterol | 0.06 mmol/L | Standard Deviation 0.23 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Low Density Lipoproteins Cholesterol | -0.25 mmol/L | Standard Deviation 0.61 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Very Low Density Lipoproteins Cholesterol | -0.17 mmol/L | Standard Deviation 0.32 |
| GFT505 120mg | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Triglycerides | -0.48 mmol/L | Standard Deviation 0.9 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Triglycerides | 0.16 mmol/L | Standard Deviation 1.12 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Very Low Density Lipoproteins Cholesterol | 0.05 mmol/L | Standard Deviation 0.23 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Non-high Density Lipoproteins Cholesterol | 0.07 mmol/L | Standard Deviation 0.67 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Low Density Lipoproteins Cholesterol | -0.01 mmol/L | Standard Deviation 0.51 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | Cholesterol | 0.02 mmol/L | Standard Deviation 0.66 |
| Placebo | Changes From Baseline to Week 52 in Lipid Parameters (Cardiovascular Risk Profile) | High Density Lipoproteins Cholesterol | -0.06 mmol/L | Standard Deviation 0.21 |
Comparison: Triglyceridesp-value: <0.00195% CI: [-0.73, -0.21]Mixed Models Analysis
Comparison: Triglyceridesp-value: <0.00195% CI: [-0.81, -0.29]Mixed Models Analysis
Comparison: Cholesterolp-value: 0.00195% CI: [-0.56, -0.14]Mixed Models Analysis
Comparison: Cholesterolp-value: <0.00195% CI: [-0.64, -0.23]Mixed Models Analysis
Comparison: Non-high Density Lipoproteins Cholesterolp-value: <0.00195% CI: [-0.67, -0.24]Mixed Models Analysis
Comparison: Non-high Density Lipoproteins Cholesterolp-value: <0.00195% CI: [-0.75, -0.32]Mixed Models Analysis
Comparison: High Density Lipoproteins Cholesterolp-value: 0.00595% CI: [0.03, 0.15]Mixed Models Analysis
Comparison: High Density Lipoproteins Cholesterolp-value: <0.00195% CI: [0.05, 0.17]Mixed Models Analysis
Comparison: Very Low Density Lipoproteins Cholesterolp-value: <0.00195% CI: [-0.26, -0.11]Mixed Models Analysis
Comparison: Very Low Density Lipoproteins Cholesterolp-value: <0.00195% CI: [-0.25, -0.09]Mixed Models Analysis
Comparison: Low Density Lipoproteins Cholesterolp-value: 0.03195% CI: [-0.38, -0.02]Mixed Models Analysis
Comparison: Low Density Lipoproteins Cholesterolp-value: 0.00995% CI: [-0.42, -0.06]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in adiponectin (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin | 4.98 μg/mL | Standard Deviation 20.25 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin | 1.90 μg/mL | Standard Deviation 8.34 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Adiponectin | 2.54 μg/mL | Standard Deviation 9.48 |
p-value: 0.45995% CI: [-2.77, 6.11]Mixed Models Analysis
p-value: 0.76495% CI: [-5.06, 3.72]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in alpha2 macroglobulin (a non-invasive marker of fibrosis and steatosis). Participants with missing data for Alpha2 Macroglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin | -0.14 g/L | Standard Deviation 0.29 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin | -0.26 g/L | Standard Deviation 0.36 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Alpha2 Macroglobulin | 0.01 g/L | Standard Deviation 0.28 |
p-value: 0.00295% CI: [-0.29, -0.01]Mixed Models Analysis
p-value: <0.00195% CI: [-0.34, -0.15]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score
Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score is based on age, hyperglycemia, BMI, platelet count, albumin level, and AST/ALT ratio. Score is calculated using the following formula: -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m\^2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×10\^9/l) - 0.66 × albumin (g/dl). A score of \<-1.455 indicates no advanced fibrosis and a score of \>0.676 indicates liver fibrosis. In below table for Angulo index and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Angulo index calculated in 82 participants is 0.06 with a standard deviation of 0.53.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score | 0.06 score on a scale | Standard Deviation 0.53 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score | -0.26 score on a scale | Standard Deviation 0.57 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Angulo Index or Non-Alcoholic Fatty Liver Disease Fibrosis Score | -0.01 score on a scale | Standard Deviation 0.51 |
p-value: 0.47195% CI: [-0.11, 0.23]Mixed Models Analysis
p-value: 0.00595% CI: [-0.42, -0.08]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK18 M30 (non-invasive markers of fibrosis and steatosis). Participants with missing data for CK18 M30 at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30 | -28.08 pmol/L | Standard Deviation 574.5 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30 | -66.40 pmol/L | Standard Deviation 432.02 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK18 M30 | -51.39 pmol/L | Standard Deviation 349.64 |
p-value: 0.59295% CI: [-86.63, 151.42]Mixed Models Analysis
p-value: 0.6195% CI: [-89.42, 152.12]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in CK 18-M65 (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65 | 104.4 U/L | Standard Deviation 804.96 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65 | -185.01 U/L | Standard Deviation 658.14 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: CK 18-M65 | -45.53 U/L | Standard Deviation 437.21 |
p-value: 0.09595% CI: [-24.99, 308.55]Mixed Models Analysis
p-value: 0.41295% CI: [-239.85, 98.71]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF)
Enhanced Liver Fibrosis (ELF) combines measurements of tissue inhibitor of metalloprotein-ases-1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) . The ELF score is calculated as : 2.278 + 0.851 ln (HA) + 0.751 ln (PIIINP) + 0.394 ln (TIMP-1). ELF score range from An ELF score of less than 7.7 indicates no fibrosis. An ELF score greater than or equal to 9.8 indicates severe fibrosis. An ELF score of 11.3 or greater indicates cirrhosis. A decrease in ELF score represents a positive outcome In below table for Enhanced Liver Fibrosis and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Enhanced Liver Fibrosis calculated in 81 analysed participants is -0.01 with a standard deviation of 0.54.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF) | -0.01 score on a scale | Standard Deviation 0.54 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF) | -0.01 score on a scale | Standard Deviation 0.64 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Enhanced Liver Fibrosis (ELF) | 0.08 score on a scale | Standard Deviation 0.7 |
p-value: 0.45795% CI: [-0.27, 0.12]Mixed Models Analysis
p-value: 0.42895% CI: [-0.28, 0.12]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI)
The Fatty Liver Index (FLI) combines triglycerides, BMI, GGT and Waist circumference. FLI is calculated as : (e0.953×loge\[triglycerides\]+0.139× Body Mass Index\[BMI\]+0.718×loge Gamma- Glutamyl Transferase \[GGT\]+0.053×waistcircumference-15.745)/ (1 +e0.953×loge\[triglycerides\]+0.139×BMI+0.718×loge \[GGT\]+0.053×waistcircumference-15.745) × 100. Calculated index range from 0 to 100. FLI score below 30 indicate absence of Fatty Liver and FLI Score of 60 and above indicates presence of Fatty Liver. In below table for Fatty Liver Index and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Fatty Liver Index calculated in 82 analysed participants is -7.94 with a standard deviation of 11.74.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI) | -7.94 score on a scale | Standard Deviation 11.74 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI) | -7.81 score on a scale | Standard Deviation 14.29 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fatty Liver Index (FLI) | 1.34 score on a scale | Standard Deviation 11.65 |
p-value: <0.00195% CI: [-13.19, -5.24]Mixed Models Analysis
p-value: <0.00195% CI: [-13.12, -5.04]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in ferritin (non-invasive markers of fibrosis and steatosis). Participants with missing data for Ferritin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin | -23.52 μg/L | Standard Deviation 145.61 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin | -19.68 μg/L | Standard Deviation 81.91 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Ferritin | -19.26 μg/L | Standard Deviation 122.57 |
p-value: 0.46695% CI: [-47.79, 21.95]Mixed Models Analysis
p-value: 0.74595% CI: [-41.07, 29.42]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in FG19 and FG21 (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG21 | 258.74 pg/mL | Standard Deviation 1138.36 |
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG19 | -27.25 pg/mL | Standard Deviation 94.19 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG19 | -26.03 pg/mL | Standard Deviation 91.59 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG21 | 319.68 pg/mL | Standard Deviation 433.63 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG19 | 11.64 pg/mL | Standard Deviation 87.1 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: FG19 and FG21 | FG21 | 73.05 pg/mL | Standard Deviation 360.41 |
Comparison: FG19p-value: 0.01895% CI: [-48.59, -4.54]Mixed Models Analysis
Comparison: FG19p-value: <0.00195% CI: [-62.61, -18.17]Mixed Models Analysis
Comparison: FG21p-value: 0.10195% CI: [-37.38, 417.52]Mixed Models Analysis
Comparison: FG21p-value: 0.05295% CI: [-2.16, 458.82]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer
Fibrometer combines Platelets, AST, ALT, ferritin, glucose (fasting plasma), Weight and gender. Patented formula. Score ranges from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for Fibrometer and for column GFT505 80mg the result should be read as : the mean of change from baseline to week 52 of Fibrometer calculated in 81 analysed participants is 0.04 with a standard deviation of 0.23.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer | 0.04 score on a scale | Standard Deviation 0.23 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer | 0 score on a scale | Standard Deviation 0.2 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrometer | 0.02 score on a scale | Standard Deviation 0.22 |
p-value: 0.53195% CI: [-0.05, 0.09]Mixed Models Analysis
p-value: 0.63895% CI: [-0.08, 0.05]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest
Fibrotest combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT with adjustment for age and gender. Fibrotest is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e\^-z). Calculated score range from 0 (no fibrosis) to 1 (severe fibrosis or cirrhosis) In below table for Fibrotest and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Fibrotest calculated in 81 participants is -0.06 with a standard deviation of 0.08.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest | -0.06 score on a scale | Standard Deviation 0.08 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest | -0.07 score on a scale | Standard Deviation 0.09 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Fibrotest | -0.01 score on a scale | Standard Deviation 0.1 |
p-value: <0.00195% CI: [-0.07, -0.02]Mixed Models Analysis
p-value: <0.00195% CI: [-0.08, -0.02]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in hyaluronic acid, N-terminal pro-peptide of collagen type III (PIIINP), and tissue inhibitor of matrix metalloprotease-1 (TIMP-1) (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | PIIINP | -0.50 ng/mL | Standard Deviation 3.43 |
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | Hyaluronic acid | 26.12 ng/mL | Standard Deviation 230.97 |
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | TIMP-1 | 15.21 ng/mL | Standard Deviation 35.38 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | PIIINP | -0.57 ng/mL | Standard Deviation 3.75 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | Hyaluronic acid | 12.14 ng/mL | Standard Deviation 48.04 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | TIMP-1 | -6.32 ng/mL | Standard Deviation 39.75 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | Hyaluronic acid | 12.49 ng/mL | Standard Deviation 48.68 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | TIMP-1 | 9.08 ng/mL | Standard Deviation 49.54 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Hyaluronic Acid, N-terminal Pro-peptide of Collagen Type III (PIIINP), and Tissue Inhibitor of Matrix Metalloprotease-1 (TIMP-1) | PIIINP | 0.29 ng/mL | Standard Deviation 4.87 |
Comparison: Hyaluronic acidp-value: 0.20395% CI: [-42.07, 8.98]Mixed Models Analysis
p-value: 0.60395% CI: [-32.49, 18.9]Mixed Models Analysis
Comparison: PIIINPp-value: 0.23595% CI: [-1.95, 0.48]Mixed Models Analysis
Comparison: PIIINPp-value: 0.19395% CI: [-2.04, 0.41]Mixed Models Analysis
Comparison: TIMP-1p-value: 0.34895% CI: [-6.81, 19.22]Mixed Models Analysis
Comparison: TIMP-1p-value: 0.02995% CI: [-27.81, 1.51]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR)
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in international normalized ratio (INR; non-invasive marker of fibrosis and steatosis). Participants with missing data for International Normalized Ratio (INR) at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR) | 0.03 ratio | Standard Deviation 0.09 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR) | -0.01 ratio | Standard Deviation 0.08 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: International Normalized Ratio (INR) | 0.03 ratio | Standard Deviation 0.39 |
p-value: 0.39395% CI: [-0.1, 0.04]Mixed Models Analysis
p-value: 0.28995% CI: [-0.11, 0.03]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in prothrombin ratio (non-invasive marker of fibrosis and steatosis). The Prothrombin ratio is the ratio of a participants measured prothrombin time (in seconds) to the normal laboratory reference prothrombin time. Participants with missing data for Prothrombin ratio at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio | -3.85 ratio | Standard Deviation 11.57 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio | 1.29 ratio | Standard Deviation 10.03 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Prothrombin Ratio | 0.51 ratio | Standard Deviation 14.28 |
p-value: 0.07595% CI: [-5.95, 0.29]Mixed Models Analysis
p-value: 0.49195% CI: [-4.29, 2.07]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest
SteatoTest combines α2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, and ALT, adjusted for patient's age, sex, weight, and height. Patented formula. Calculated score range from 0 (no steatosis) to 1 (severe steatosis) In below table for Steatotest and for column GFT505 80mg the result should be read as: the mean of change from baseline to week 52 of Steatotest calculated in 81 participants is -0.09 with a standard deviation of 0.11.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest | -0.09 score on a scale | Standard Deviation 0.11 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest | -0.08 score on a scale | Standard Deviation 0.15 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Steatotest | 0.03 score on a scale | Standard Deviation 0.11 |
p-value: <0.00195% CI: [-0.15, -0.07]Mixed Models Analysis
p-value: <0.00195% CI: [-0.15, -0.07]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg, the changes from baseline to week 52, in total bilirubin and conjugated bilirubin (non-invasive markers of fibrosis and steatosis).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Total bilirubin | -1.53 umol/L | Standard Deviation 3.66 |
| GFT505 80mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Conjugated bilirubin | -0.35 umol/L | Standard Deviation 1.26 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Total bilirubin | -1.38 umol/L | Standard Deviation 4.85 |
| GFT505 120mg | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Conjugated bilirubin | -0.15 umol/L | Standard Deviation 1.24 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Total bilirubin | -1.46 umol/L | Standard Deviation 3.77 |
| Placebo | Changes From Baseline to Week 52 in Non-invasive Markers of Fibrosis and Steatosis: Total Bilirubin and Conjugated Bilirubin | Conjugated bilirubin | -0.26 umol/L | Standard Deviation 1.05 |
Comparison: Total bilirubinp-value: 0.83195% CI: [-1.39, 1.12]Mixed Models Analysis
Comparison: Total bilirubinp-value: 0.75495% CI: [-1.07, 1.47]Mixed Models Analysis
Comparison: Conjugated Bilirubinp-value: 0.84895% CI: [-0.36, 0.3]Mixed Models Analysis
Comparison: Conjugated Bilirubinp-value: 0.51195% CI: [-0.22, 0.45]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Outcomes Related to Biochemistry
To evaluate after 52 weeks of daily administration of GFT505 80mg or GFT505 120mg the changes from baseline to week 52, in secondary outcomes related to biochemistry
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII | -1.79 mg/dL | Standard Deviation 3.91 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo B | -12.80 mg/dL | Standard Deviation 20.87 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Small dense Low Density Lipoproteins | -2.09 mg/dL | Standard Deviation 11.02 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/B | -1.44 mg/dL | Standard Deviation 2.98 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/nonB | -0.35 mg/dL | Standard Deviation 1.79 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo A1 | 1.63 mg/dL | Standard Deviation 15.59 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E | -1.72 mg/dL | Standard Deviation 2.75 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo AII | -0.15 mg/dL | Standard Deviation 6.63 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E/B | -1.43 mg/dL | Standard Deviation 2.43 |
| GFT505 80mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Lp(a) | -0.57 mg/dL | Standard Deviation 12.24 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/B | -0.65 mg/dL | Standard Deviation 2.98 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo A1 | 2.85 mg/dL | Standard Deviation 20.42 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo B | -8.42 mg/dL | Standard Deviation 16.03 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo AII | 4.25 mg/dL | Standard Deviation 4.36 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII | -0.69 mg/dL | Standard Deviation 3.42 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/nonB | -0.04 mg/dL | Standard Deviation 0.76 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Small dense Low Density Lipoproteins | -2.62 mg/dL | Standard Deviation 6.08 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Lp(a) | -0.91 mg/dL | Standard Deviation 13.75 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E | -1.38 mg/dL | Standard Deviation 2.99 |
| GFT505 120mg | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E/B | -1.48 mg/dL | Standard Deviation 2.64 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Small dense Low Density Lipoproteins | 0.60 mg/dL | Standard Deviation 7.52 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo AII | -3.36 mg/dL | Standard Deviation 4.82 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo A1 | -3.90 mg/dL | Standard Deviation 16.53 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Lp(a) | 0.80 mg/dL | Standard Deviation 4.46 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo B | 0.94 mg/dL | Standard Deviation 14.29 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/B | 0.53 mg/dL | Standard Deviation 3.05 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E/B | -0.21 mg/dL | Standard Deviation 2.59 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII/nonB | 0.24 mg/dL | Standard Deviation 2.53 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo CIII | 0.77 mg/dL | Standard Deviation 4.3 |
| Placebo | Changes From Baseline to Week 52 in Outcomes Related to Biochemistry | Apo E | -0.29 mg/dL | Standard Deviation 3.67 |
Comparison: Apo A1p-value: 0.03895% CI: [0.31, 11.14]Mixed Models Analysis
Comparison: Apo A1p-value: 0.01295% CI: [1.59, 12.55]Mixed Models Analysis
Comparison: Apo Bp-value: <0.00195% CI: [-17.56, -7.25]Mixed Models Analysis
Comparison: Apo Bp-value: <0.00195% CI: [-14.81, -4.41]Mixed Models Analysis
Comparison: Apo AIIp-value: <0.00195% CI: [2.14, 4.96]Mixed Models Analysis
Comparison: Apo AIIp-value: <0.00195% CI: [4.67, 7.53]Mixed Models Analysis
Comparison: Apo CIIIp-value: <0.00195% CI: [-3.29, -1.25]Mixed Models Analysis
Comparison: Apo CIIIp-value: 0.00495% CI: [-2.52, -0.49]Mixed Models Analysis
Comparison: Apo CIII/Bp-value: <0.00195% CI: [-2.63, -0.92]Mixed Models Analysis
Comparison: Apo CIII/Bp-value: 0.00995% CI: [-2, -0.29]Mixed Models Analysis
Comparison: Apo CIII/nonBp-value: 0.00295% CI: [-0.75, -0.17]Mixed Models Analysis
Comparison: Apo CIII/nonBp-value: 0.00895% CI: [-0.68, -0.1]Mixed Models Analysis
Comparison: Small dense Low Density Lipoproteinsp-value: 0.06995% CI: [-4.89, 0.19]Mixed Models Analysis
Comparison: Small dense Low Density Lipoproteinsp-value: 0.0195% CI: [-5.95, -0.84]Mixed Models Analysis
Comparison: Lp(a)p-value: 0.54995% CI: [-1.93, 3.61]Mixed Models Analysis
Comparison: Lp(a)p-value: 0.72895% CI: [-2.28, 3.26]Mixed Models Analysis
Comparison: Apo Ep-value: <0.00195% CI: [-2.14, -0.61]Mixed Models Analysis
Comparison: Apo Ep-value: 0.00495% CI: [-1.89, -0.36]Mixed Models Analysis
Comparison: Apo E/Bp-value: <0.00195% CI: [-1.82, -0.53]Mixed Models Analysis
Comparison: Apo E/Bp-value: 0.00195% CI: [-1.72, -0.43]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in beta2-microglobulin (safety marker; renal function parameter). Participants with missing data for Beta2-microglobulin at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter) | -22.26 μg/L | Standard Deviation 326.42 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter) | 0.11 μg/L | Standard Deviation 466.43 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Beta2-microglobulin (Renal Function Parameter) | -83.48 μg/L | Standard Deviation 279.31 |
p-value: 0.32595% CI: [-8.73, 146.6]Mixed Models Analysis
p-value: 0.06695% CI: [-6.06, 192.49]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in blood urea nitrogen (BUN; safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter) | 0.61 mmol urea/L | Standard Deviation 1.28 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter) | 0.67 mmol urea/L | Standard Deviation 1.22 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Blood Urea Nitrogen (BUN; Renal Function Parameter) | -0.17 mmol urea/L | Standard Deviation 1.14 |
p-value: <0.00195% CI: [0.47, 1.15]Mixed Models Analysis
p-value: <0.00195% CI: [0.5, 1.19]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine clearance (safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter) | -0.06 mL/min | Standard Deviation 0.94 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter) | -0.56 mL/min | Standard Deviation 2.22 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Creatinine Clearance (Renal Function Parameter) | -0.09 mL/min | Standard Deviation 0.62 |
p-value: 0.86195% CI: [-0.37, 0.44]Mixed Models Analysis
p-value: 0.05295% CI: [-0.81, 0]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in creatinine (safety markers; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter) | 2.03 μmol/L | Standard Deviation 7.89 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter) | 5.61 μmol/L | Standard Deviation 8.18 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Creatinine (Renal Function Parameter) | 1.27 μmol/L | Standard Deviation 7.85 |
p-value: 0.55395% CI: [-1.61, 3.01]Mixed Models Analysis
p-value: <0.00195% CI: [1.97, 6.64]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in cystatin C (safety marker; renal function parameter). Participants with missing data for Cystatin C at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter) | 0.05 mg/L | Standard Deviation 0.1 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter) | 0.04 mg/L | Standard Deviation 0.22 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Cystatin C (Renal Function Parameter) | 0.04 mg/L | Standard Deviation 0.13 |
p-value: 0.84295% CI: [-0.04, 0.04]Mixed Models Analysis
p-value: 0.58995% CI: [-0.03, 0.05]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in N-terminal prohormone of brain natriuretic peptide (NT-proBNP; safety marker; cardiac function parameter). Participants with missing data for NT-proBNP at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter) | 1.54 pmol/L | Standard Deviation 4.16 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter) | 0.38 pmol/L | Standard Deviation 4.81 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP; Cardiac Function Parameter) | -1.24 pmol/L | Standard Deviation 5.35 |
p-value: <0.00195% CI: [1.1, 3.72]Mixed Models Analysis
p-value: 0.01995% CI: [0.26, 2.91]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in troponin T (safety marker; cardiac function parameter). Participants with missing data for Troponin T at baseline (Visit 2) or Visit 8 were not imputed in the analysis explaining the difference with the number of participants reported in the Efficacy Evaluable Set of the Participant Flow.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter) | 0 μg/L | Standard Deviation 0 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter) | 0 μg/L | Standard Deviation 0 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Troponin T (Cardiac Function Parameter) | 0 μg/L | Standard Deviation 0 |
p-value: 0.44795% CI: [0, 0]Mixed Models Analysis
p-value: 0.75895% CI: [0, 0]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter)
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in uric acid (safety marker; renal function parameter).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Safety population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter) | 0 mmol/L | Standard Deviation 0.06 |
| GFT505 120mg | Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter) | 0.01 mmol/L | Standard Deviation 0.05 |
| Placebo | Changes From Baseline to Week 52 in Safety Markers: Uric Acid (Renal Function Parameter) | -0.01 mmol/L | Standard Deviation 0.06 |
p-value: 0.47395% CI: [-0.01, 0.02]Mixed Models Analysis
p-value: 0.12495% CI: [0, 0.03]Mixed Models Analysis
Secondary
Changes From Baseline to Week 52 in the Stages of Fibrosis
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in stages of fibrosis (based on Non-Alcoholic Steatohepatitis Clinical Research Network \[NASH CRN\] scoring). Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GFT505 80mg | Changes From Baseline to Week 52 in the Stages of Fibrosis | -0.23 Change in fibrosis score | Standard Deviation 0.84 |
| GFT505 120mg | Changes From Baseline to Week 52 in the Stages of Fibrosis | -0.06 Change in fibrosis score | Standard Deviation 0.96 |
| Placebo | Changes From Baseline to Week 52 in the Stages of Fibrosis | -0.23 Change in fibrosis score | Standard Deviation 0.9 |
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.354395% CI: [0.265, 1.609]Regression, Logistic
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.57895% CI: [0.547, 2.953]Regression, Logistic
Secondary
Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points
To evaluate the number of participants with at least a 2 point decrease from baseline in Non-alcoholic Fatty Liver Disease Activity Score (NAS) after 52 weeks of daily administration of GFT505 80mg or 120mg. The NAS refers to the severity of ongoing liver injury as assessed by a liver biopsy and is used to assess the activity of the disease. It is based on the NASH CRN methodology for scoring the severity of steatosis (score of 0 to 3), inflammation (score of 0 to 3), and hepatocellular ballooning (score of 0 to 2), with a maximum score of 8. A total NAS score of five or greater correlates with the diagnosis of steatohepatitis. In table below for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 2 participants (out of 10 participants analysed with a baseline NAS at 3) had at Least 2 points decrease on their NAS after 52 weeks of daily administration of GFT505 80mg. It corresponds to 20% (2 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GFT505 80mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 2 Participants |
| GFT505 80mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 11 Participants |
| GFT505 80mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Severe (Non-alcoholic Fatty Liver Disease Activity Score 6-8) | 8 Participants |
| GFT505 80mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Total | 21 Participants |
| GFT505 120mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Total | 26 Participants |
| GFT505 120mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 2 Participants |
| GFT505 120mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Severe (Non-alcoholic Fatty Liver Disease Activity Score 6-8) | 12 Participants |
| GFT505 120mg | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 12 Participants |
| Placebo | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Total | 21 Participants |
| Placebo | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 9 Participants |
| Placebo | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Severe (Non-alcoholic Fatty Liver Disease Activity Score 6-8) | 7 Participants |
| Placebo | Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 5 Participants |
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.858695% CI: [0.493, 2.339]Regression, Logistic
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.226595% CI: [0.747, 3.432]Regression, Logistic
Secondary
Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in lobular inflammation score of at least 1 point between baseline and Week 52. Lobular inflammation is assessed by a liver biopsy and evaluated on a scale of 0 to 3. A score of 0 indicating the absence of inflammation loci, while a score of 3 is indicative of a higher degree of inflammation with more than 4 inflammation loci 200 x field. In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Lobular Inflammation Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GFT505 80mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 1 Participants |
| GFT505 80mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 10 Participants |
| GFT505 80mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 14 Participants |
| GFT505 80mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Total | 25 Participants |
| GFT505 120mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Total | 29 Participants |
| GFT505 120mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 2 Participants |
| GFT505 120mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 16 Participants |
| GFT505 120mg | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 11 Participants |
| Placebo | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Total | 27 Participants |
| Placebo | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 8 Participants |
| Placebo | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 12 Participants |
| Placebo | Number of Participants With Decrease in Lobular Inflammation Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 7 Participants |
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.522995% CI: [0.161, 2.529]Regression, Logistic
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.564695% CI: [0.421, 4.875]Regression, Logistic
Secondary
Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in steatosis score of at least 1 point between baseline and Week 52. Steatosis is assessed by a liver biopsy and evaluated on a scale of 0 to 3 with higher scores indicating more severe steatosis. A score of 0 indicating a lower severity with low parenchymal involvement (\<5%), while a score of 3 is indicative of higher involvment/severity (\> 66%). In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 1 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease Steatosis Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GFT505 80mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Total | 17 Participants |
| GFT505 80mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 13 Participants |
| GFT505 80mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 3 Participants |
| GFT505 80mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 1 Participants |
| GFT505 120mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 10 Participants |
| GFT505 120mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 10 Participants |
| GFT505 120mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 1 Participants |
| GFT505 120mg | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Total | 21 Participants |
| Placebo | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 3 Participants |
| Placebo | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 12 Participants |
| Placebo | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Total | 15 Participants |
| Placebo | Number of Participants With Decrease in Steatosis Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 0 Participants |
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.523195% CI: [0.267, 1.958]Regression, Logistic
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.845995% CI: [0.415, 2.924]Regression, Logistic
Secondary
Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52
To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, number of participants with a decrease in ballooning score of at least 1 point between baseline and Week 52. Ballooning is assessed by a liver biopsy and evaluated on a scale of 0 to 2 with higher scores indicating more severe ballooning (0: No ballooned cells, 1: Few \[rare but definite\] ballooned hepatocytes; 2: Many ballooned cells/prominent ballooning). In below table and for helping how results are reported, as an example for raw Mild (Nonalcoholic Fatty Liver Disease Activity Score 3) and the column GFT505 80mg the result should be read as : 4 participants (out of 10 participants analysed with a baseline NAS at 3) had at least 1 point decrease of Ballooning Score after 52 weeks of daily administration of GFT505 80mg. It corresponds to 10% (1 out of 10).
Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)
Population: Efficacy evaluable set
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GFT505 80mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 4 Participants |
| GFT505 80mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 17 Participants |
| GFT505 80mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 10 Participants |
| GFT505 80mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Total | 31 Participants |
| GFT505 120mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Total | 30 Participants |
| GFT505 120mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 3 Participants |
| GFT505 120mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 12 Participants |
| GFT505 120mg | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 15 Participants |
| Placebo | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Total | 24 Participants |
| Placebo | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Moderate (Non-Alcoholic Fatty Liver Disease Activity Score 4-5) | 13 Participants |
| Placebo | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Severe (Non-Alcoholic Fatty Liver Disease Activity Score 6-8) | 5 Participants |
| Placebo | Title: Number of Participants With Decrease in Ballooning Score of at Least 1 Point Between Baseline and Week 52 | Mild (Non-Alcoholic Fatty Liver Disease Activity Score 3) | 6 Participants |
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 0.198395% CI: [0.088, 1.656]Regression, Logistic
Comparison: Population with baseline Non-Alcoholic Fatty Liver Disease Activity Score greater than or equal to 4p-value: 195% CI: [0.288, 3.466]Regression, Logistic